Corporate News

07 December

02 December

Director PDMR Dealing (pdf)

30 November

30 November

Interim Results for the six months ended 30 September 2020 (pdf)

23 November

17 November

UK-RTC update (pdf)

16 November

Holding(s) in Company (pdf)

16 November

Holding(s) in Company (pdf)

13 November

12 November

UK-RTC statement (pdf)

12 November

Response to media comment (pdf)

11 November

Investor presentation – Q&A Update (pdf)

09 November

06 November

03 November

Chinese approval for self-test use of Food Detective® test (pdf)

30 October

29 October

Holding(s) in Company (pdf)

28 October

Trading update and notice of interim results (pdf)

20 October

Notice of Trading Update and Investor Presentation (pdf)

20 October

19 October

UK-RTC contract for the Supply of Goods (pdf)

14 October

09 October

07 October

UK Government contract for UK-Rapid Test Consortium (pdf)

06 October

Holding(s) in Company (pdf)

06 October

UK Government contract for UK-Rapid Test Consortium (pdf)

02 October

Preliminary report published by Ulster University (pdf)

29 September

Investor Presentation (pdf)

15 September

15 September

TR-1 Standard form for notification of major holdings (pdf)

14 September

10 September

Holding(s) in Company (pdf)

07 September

Statement regarding Share Price Movement (pdf)

07 September

Completion of self-test usability study for AbC-19™ Rapid test (pdf)

03 September

CE-Mark for Mologic COVID-19 antibody test (pdf)

01 September

26 August

26 August

24 August

21 August

WHO Prequalification received (pdf)

30 July

Update on progress of UK-Rapid Test Consortium (pdf)

24 July

Exercise of options and Total Voting Rights (pdf)

23 July

Notice of AGM and posting of Annual Report (pdf)

20 July

Investor presentation (pdf)

14 July

Final Results for the year ended 31 March 2020 (pdf)

10 July

Result of General Meeting (pdf)

10 July

Notice of Results (pdf)

08 July

Result of Open Offer – full take up (pdf)

02 July

Approval for sale in India (pdf)

29 June

Update on progress of UK-Rapid Test Consortium (pdf)

22 June

Publication of Shareholder Circular (pdf)

22 June

Investor presentation (pdf)

19 June

Fundraising to raise gross proceeds of up to £11 million (pdf)

09 June

Trading Update (pdf)

03 June

Update on progress of UK-Rapid Test Consortium (pdf)

01 June

Holding(s) in Company (pdf)

27 May

Statement regarding share price movement (pdf)

22 May

Exercise of options TVR and issue of equity (pdf)

07 May

04 May

30 April

29 April

Holding(s) in Company (pdf)

28 April

Holding(s) in Company (pdf)

28 April

VISITECT® CD4 Advanced Disease Supply Agreement with Clinton Health Access Initiative, Inc_ (pdf)

27 April

CE-Mark of COVID-19 ELISA antibody test (pdf)

20 April

Material Transfer Agreement with Mologic on COVID-19 antibody test (pdf)

20 April

Holding(s) in Company (pdf)

16 April

Holding(s) in Company (pdf)

16 April

Holding(s) in Company (pdf)

14 April

Holding(s) in Company (pdf)

09 April

Memorandum of Understanding COVID-19 Consortium (pdf)

06 April

VISITECT® CD4 Advanced Disease evaluation in Malawi, Zimbabwe and the Democratic Republic of Congo (pdf)

06 April

Holding(s) in Company (pdf)

02 April

Trading Update (pdf)

02 April

Chinese Approval for Food Detective test (pdf)

24 January

Grant of options (pdf)

17 January

Nigerian Ministry of Health approval for VISITECT® CD4 350 test (pdf)

2019

02 December

Interim Results for the six months ended 30 September 2019 (pdf)

02 December

Nigerian order for VISITECT® CD4 (pdf)

25 November

Update on Allergy test menu (pdf)

21 November

Investor results briefing (pdf)

22 October

22 October

15 October

Holding(s) in Company (pdf)

14 October

Holding(s) in Company (pdf)

14 October

Holding(s) in Company (pdf)

11 October

Holding(s) in Company (pdf)

10 October

Result of General Meeting (pdf)

27 September

Notice of AGM and Posting of Annual Report (pdf)

23 September

Placing & Subscription and Notice of General Meeting (pdf)

23 September

Final Results for the Year Ended 31 March 2019 (pdf)

16 September

Update on VISITECT® CD4 Advanced Disease (pdf)

10 September

Second Purchase Order for Chinese Food Detective® test (pdf)

20 August

First Purchase Order for VISITECT® CD4 Advanced Disease Test (pdf)

16 August

Announcement of Results, trading update and Nigerian order for VISITECT® CD4 (pdf)

06 June

Announcement of Results (pdf)

05 June

Holding(s) in Company (pdf)

03 June

Holding(s) in Company (pdf)

22 May

Subscription to raise c.£635,000 (pdf)

17 April

Trading Update (pdf)

18 March

CE-Mark for VISITECT® CD4 Advanced Disease test (pdf)

06 March

VISITECT® CD4 update (pdf)

01 March

Board Appointment (pdf)

29 January

VISITECT® CD4 Advanced Disease test update (pdf)

2018

10 December

Directorate Change (pdf)

03 December

Interim results for six months ended 30 Sep 2018 (pdf)

19 October

Holding(s) in Company (pdf)

10 October

27 September

Allergy CE-Mark and first Purchase Order (pdf)

14 September

10 September

Holding(s) in Company (pdf)

06 August

Final Results for the year ended 31 March 2018 (pdf)

06 August

VISITECT® CD4 Advanced Disease Development Update (pdf)

18 July

VISITECT® CD4 commercialisa (pdf)

02 July

Notice of Results (pdf)

28 June

Disposal of infectious disease business for up to £2.175m (pdf)

21 May

VISITECT® CD4 development update (pdf)

08 May

Allersys CE Mark (pdf)

02 May

Closure of Omega Diagnostics GmbH (pdf)

24 April

PDMR Dealing (pdf)

24 April

Holding(s) in Company (pdf)

23 April

Holding(s) in Company (pdf)

23 April

Director_PDMR Shareholding 2 (pdf)

23 April

Holding(s) in Company (pdf)

23 April

Director_PDMR Shareholding (pdf)

20 April

Allersys Distribution Agreement (pdf)

10 April

Strategic Review of operations and Trading Update (pdf)

10 April

Price Monitoring Extension (pdf)

12 January

Holding(s) in Company (pdf)

2017

21 December

Allersys® CE-Mark (pdf)

14 December

CEO succession (pdf)

29 November

VISITECT CD4 CE-Mark (pdf)

01 November

Change of Registered Office (pdf)

23 October

16 October

US Supply Agreement (pdf)

10 October

Holding(s) in Company (pdf)

05 September

29 August

18 July

Result of General Meeting (pdf)

17 July

Result of Open Offer (pdf)

06 July

Sale and leaseback of the building owned by Omega GmbH (pdf)

30 June

Result of Proposed Fundraising (pdf)

30 June

Proposed Fundraising (pdf)

30 June

Final Results for the year ended 31 March 2017 (pdf)

25 April

Trading Update and Notice of Results (pdf)

21 April

Holding(s) in Company (pdf)

27 March

VISITECT® Malaria CE-Mark and successful Indian FDA inspection (pdf)

07 March

Holding(s) in Company (pdf)

27 February

Holding(s) in Company (pdf)

27 January

Update on discussions with Immunodiagnostic Systems Holdings plc (pdf)

11 January

ISO accreditation for manufacturing facility in Pune, India (pdf)

2016

24 November

Holding(s) in Company (pdf)

17 October

10 August